Technology

Galera

$10.15
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.15 (+1.50%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Galera and other stocks, options, and ETFs commission-free!

About GRTX

Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. The firm involves in the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis and cancer. Its product candidate, GC4419, reduces severe oral mucositis in patients with head and neck cancer undergoing radiation therapy and also receiving cisplatin, a chemotherapy drug. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA. The listed name for GRTX is Galera Therapeutics, Inc. Common Stock.

CEO
J. Mel Sorensen
Employees
32
Headquarters
Malvern, Pennsylvania
Founded
2009
Market Cap
254.02M
Price-Earnings Ratio
Dividend Yield
Average Volume
55.04K
High Today
$10.34
Low Today
$9.95
Open Price
$10.05
Volume
629.90K
52 Week High
$18.57
52 Week Low
$5.58

Collections

GRTX Earnings

-$51.43
-$34.29
-$17.14
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 9, Pre-Market

You May Also Like

PNI
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure